Results 171 to 180 of about 131,929 (338)
Mononuclear cell subsets and coronary artery lesions in Kawasaki disease. [PDF]
Susumu Furukawa+2 more
openalex +1 more source
Epidemiology of Kawasaki Disease
Kawasaki disease is an acute systemic vasculitis involving mainly the small and medial arteries. It usually presents with acute inflammatory symptoms and signs in infancy and early childhood, and results in coronary arterial lesions in 20% and about 5% of patients during the acute and convalescent stages, respectively.
openaire +4 more sources
This review focuses on the enhanced polyol pathway and the formation of glucoselysine and discusses its biochemical characteristics and clinical significance. ABSTRACT Advanced glycation end‐products (AGEs) have been extensively studied because of their close association with the onset and progression of diabetic complications.
Hiroko Yamaguchi, Ryoji Nagai
wiley +1 more source
Management of Kawasaki disease in the British Isles. [PDF]
Rami Dhillon+3 more
openalex +1 more source
Urinary albumin/creatinine ratio significantly decreased, increased, and again decreased during the period of the 1st administration, withdrawal, and re‐administration of tofogliflozin, respectively. In contrast, serum creatinine increased during the 1st administration and re‐administration period of tofogliflozin and throughout the observation period,
Ayako Shigeta+12 more
wiley +1 more source
Paciente masculino de 3 años de edad, con fiebre de 5 días de duración ¨¡que no le baja con la medicación doctorcito!¨ y exantema polimorfo [PDF]
Kawasaki disease is an acute systemic vasculitis that presents in childhood, with uncertain etiology. It is the main cause of acquired heart disease in children in developed countries; it presents with coronary artery aneurysms in up to 25% of untreated ...
Barzallo Inca, John Dario
core
Participants (2,159) were assigned to COVID‐19 GDM (n = 413) and COVID‐19 NGT (n = 1,746) groups. The sensitivity, specificity, positive predictive value, and negative predictive value of the Japanese COVID‐19 GDM strategy were 35.4, 90.5, 68.9, and 70.3%, respectively.
Yoshifumi Kasuga+21 more
wiley +1 more source